ADVERTISEMENT

Sun Pharma Gets U.S. FDA Nod To Market Generic Medication

Sun Pharma received approval to market a generic medication used in the treatment of multiple myeloma.

<div class="paragraphs"><p>A bird flies past the logo of Sun Pharma installed on the facade of its corporate office in Mumbai. (Photo: Francis Mascarenhas/Reuters)</p></div>
A bird flies past the logo of Sun Pharma installed on the facade of its corporate office in Mumbai. (Photo: Francis Mascarenhas/Reuters)

Sun Pharmaceutical Industries on Friday said its subsidiary has received approval from the U.S. health regulator to market a generic medication used in the treatment of multiple myeloma.

The company has received final approval from the U.S. Food and Drug Administration for the generic lenalidomide capsules in multiple strengths, Sun Pharma said in a statement.

In June 2021, Sun Pharma entered into a settlement with Celgene Corporation to resolve the patent litigation regarding its generic lenalidomide capsules.

Under the terms of this settlement, Celgene granted Sun Pharma a license to patents required to manufacture and sell certain limited quantities of generic lenalidomide capsules in the U.S., beginning sometime after March 2022.

In addition, the license allows Sun Pharma to manufacture and sell an unlimited quantity of generic lenalidomide capsules in the U.S. beginning Jan. 31, 2026.

Shares of Sun Pharma were trading 0.48% down at Rs 1,002 apiece on the BSE.